Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

UCB Pharma Inc. and the Food and Drug Administration recently issued a “Dear health care professional” letter advising health care professionals of the risk of dispensing errors between lopinavir/ritonavir (Kaletra), an antiretroviral, and levetiracetam (Keppra), an antiepileptic drug.

UCB Pharma and FDA issue advisory letter